NEW YORK--(BUSINESS WIRE)--Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), encourages biotech and pharmaceutical companies that are ...

Blood clotting disorders can be inherited or acquired and lead to either excessive bleeding or too much clotting.

NBDF’s Advisory Panels give biopharma direct access to patients, caregivers, and clinicians within the bleeding disorders community Pathway to Cures (P2C), the venture philanthropy fund of the ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is ...

Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. ST. LOUIS – When it comes to bleeding ...

Adults living with bleeding disorders in Hampton Roads now have a new option for specialized care without the long drive many people have faced for years. Bleeding disorders, including hemophilia and ...